Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide is available in the UK in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Treatment begins at 2.5 mg and the prescriber works upward through those steps over several months, based on how your body responds. These are prescription-only medicines; a clinician assesses which strength is appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The NHS tirzepatide medicines page sets out the approved dose ladder clearly. You start at 2.5 mg once a week for four weeks. That first pen is not expected to produce dramatic weight loss, the point is to introduce the medicine gently and reduce the chance of nausea and other gastrointestinal side effects in the early weeks.
After that, the typical progression moves through 5 mg, 7.5 mg, 10 mg, and 12.5 mg, each held for at least four weeks before the next step upward. The ceiling is 15 mg per week. A prescriber may slow that schedule if side effects are troublesome, or hold a dose for longer if it is working well enough and you are tolerating it comfortably. The decision belongs to your clinician, not to the calendar alone.
One misconception worth addressing gently: some people assume the lower doses are weaker versions of the same medicine, almost like a lesser treatment. They are not. Each strength is the same dual GIP and GLP-1 receptor agonist; the stepped approach exists because the body adjusts better that way, and the evidence for meaningful weight loss runs across the entire range. You can read more about how individual strengths fit real-world prescribing on the tirzepatide strengths overview.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity to tirzepatide at 5 mg, 10 mg or 15 mg, or to placebo, over 72 weeks. Average weight loss was roughly 15% at 5 mg, around 19.5% at 10 mg, and approximately 20–21% at 15 mg. All three active doses outperformed placebo by a considerable margin. The headline figure most people quote (the roughly 20% reduction) applies specifically to the highest dose group, not to every participant across every strength.
NICE reviewed this evidence in detail when it recommended tirzepatide for NHS use in England (TA1026, published December 2024). The appraisal noted that efficacy scales with dose, though individual response varies; reaching the highest tolerated dose matters, but even lower maintenance doses produce clinically meaningful results for many people. If you are weighing up how the data compares to other options, the Mounjaro treatment page covers the broader evidence picture.
For context on what that evidence means in practice, the guide to which strength is used for weight loss explains how prescribers think about target dose versus maintenance dose in day-to-day clinical decisions.
No website can answer that for an individual. The strength a prescriber settles on depends on how well you tolerate earlier doses, your starting weight, any other medicines you take, and how your weight responds over time. A number of people reach 15 mg and stay there; others do well at 10 mg and their prescriber judges there is no clinical reason to push higher.
The Mounjaro dosing guide goes into more detail on how those conversations typically unfold. For a practical look at the 5 mg dose specifically (the first therapeutic step after the starter month) the 5 mg page is worth reading before your consultation.
Eligibility for private treatment sits at a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol; lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is never the whole picture, a prescriber reviews your full health profile. If you are thinking about the cost side of things, a Mounjaro price comparison sets out what drives the variation you will see across providers.
At nume, every dose step is reviewed by a GPhC-registered Independent Prescriber before a repeat is dispatched. A real clinician reads your responses (your weight, any side effects, how you have been finding the current pen) before approving the next strength. Orders placed before midday on a working day are dispatched the same day once clinically approved, arriving the following working day via tracked DPD delivery in plain, unbranded packaging.
Our clinical team is described on the clinical team profile page if you want to know who is reviewing your treatment. You can also browse the weight-loss treatment overview for a broader picture of what the service involves before deciding whether to proceed. When you are ready, check your eligibility for a free consultation and our prescribers will take it from there.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.